Lisinopril STELLA 10 mg

Lisinopril is an angiotensin converting enzyme (ACE) inhibitor. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decrease aldosterone secretion.

Pack size Box of 100 tablets
Shelf-life 36 months
Composition Lisinopril
Dosage forms and strengths Tablet: 10 mg.
Product code :



  • Monotherapy or in combination to treat: Hypertension, symptomatic congestive heart failure resistant to or inadequately controlled by cardiac glycosides and diuretics, acute myocardial infarction who are hemodynamically stable (in conjunction with thrombolytic agents, aspirin, and/or β-adrenergic blocking agents).
  • Diabetic nephropathy.



  • Hypertension: In adults not receiving a diuretic: 5–10 mg once daily, maintenance with dose of 20–40 mg daily, given as a single dose. In a patient already receiving a diuretic: discontinue diuretic therapy 2–3 days before initiating Lisinopril STELLA 10 mg (If diuretic therapy cannot be discontinued: 5 mg daily, sodium intake can be increased prior to initiating Lisinopril STELLA 10 mg).
  • Congestive heart failure: 2.5–5 mg daily, the effective dosage of lisinopril in adults is 5–40 mg daily, given as a single dose.
  • Acute myocardial infarction: A 5 mg dose of lisinopril should be given within 24 hours of onset of symptoms of myocardial infarction followed by a 5 and 10 mg dose 24 and 48 hours later, respectively. Maintenance with dose of 10 mg daily; continue for 6 weeks.
  • Diabetic nephropathy: The initial dose is 2.5 mg once daily. In normotensive type 1 diabetics the maintenance dose is 10 mg daily, increased to 20 mg daily if necessary to achieve a sitting diastolic blood pressure below 75 mmHg. In hypertensive type 2 diabetics, the dose should be adjusted to achieve a sitting diastolic blood pressure below 90 mmHg.

Children aged 6 to 12 years: 70 mcg/kg (up to 5 mg) once daily, increase at intervals of 1 to 2 weeks to a maximum of 600 mcg/kg or 40 mg once daily. Children between 12 and 18 years of age: 2.5 mg daily, increase as necessary to a maximum of 40 mg daily.

In adults with renal impairment: creatinine clearance (Clcr) 31 to 80 ml/minute: 5 to 10 mg once daily. Clcr 10 to 30 ml/minute: 2.5 to 5 mg once daily. Clcr less than 10 ml/minute or on dialysis: 2.5 mg once daily. Lisinopril should not be given to children with a glomerular filtration rate of less than 30 ml/min/1.73 m2.


Lisinopril STELLA 10 mg is administered orally.

  • Known hypersensitivity to lisinopril, other ACE inhibitors, or to any ingredient.
  • Patients with a history of angioedema related to previous treatment with an ACEI.
  • Patients with hereditary or idiopathic angioedema.
  • Patients with aortic stenosis or hypertropic cardiomyopathy, unilateral or bilateral renal artery stenosis.
  • Pregnancy and lactation.
  • Common: Headache. Cough (dry, continuing).
  • Less common: Nausea, dysgeusia (loss of taste), diarrhoea. Hypotension. Skin rash, maculopapular, urticarial rash, with or without itching. Fatigue, proteinuria, fever or joint pain.
  • Rare: Angioedema. Hyperkalemia. Confusion, nervousness, numbness or tingling in hand, feet or lips. Shortness of breath, difficult breathing, chest pain. Neutropenia, agranulocytosis. Hepatotoxicity, jaundice, cholestasis, hepatic necrosis and hepatocellular injury.
  • Use with caution in patients with obstruction in the outflow tract of the left ventricle, preexisting renal impairment, and concomitant diuretic, acute myocardial infarction who have evidence of renal dysfunction, kidney failure, diabetic patients receiving concomitant therapy with ACE inhibitors and insulin or oral antidiabetic agents, hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension. Hyperkalemia.
  • Patients should be aware of how they react to drug before driving or operating machinery.